Table 4.

Association between mortality and hormone therapy (HT) adjusted for education and shown separately for each age group within twin pairs.

	Year
	2000	2005
Age 51–55, HR (95% CI)
No HT	1 (ref)
Systemic HT	1.37 [0.76; 2.44]
Local HT	1.22 [0.41; 3.65]
Age 56–60, HR (95% CI)
No HT	1 (ref)	1 (ref)
Systemic HT	0.66 [0.37; 1.17]	0.92 [0.42; 2.01]
Local HT	1.00 [0.35; 2.83]	2.84 [1.20; 6.73]
Age 61–65, HR (95% CI)
No HT	1 (ref)	1 (ref)
Systemic HT	1.08 [0.61; 1.90]	0.77 [0.38; 1.57]
Local HT	1.05 [0.53; 2.06]	0.79 [0.39; 1.58]
Age 66–70, HR (95% CI)
No HT	1 (ref)	1 (ref)
Systemic HT	0.73 [0.40; 1.34]	0.84 [0.41; 1.70]
Local HT	1.71 [0.67; 4.36]	1.15 [0.62; 2.13]
Age 71–75, HR (95% CI)
No HT	1 (ref)	1 (ref)
Systemic HT	0.99 [0.55; 1.80]	0.74 [0.35; 1.58]
Local HT	0.91 [0.38; 2.14]	0.97 [0.47; 2.00]
Age 76–80, HR (95% CI)
No HT	1 (ref)	1 (ref)
Systemic HT	0.55 [0.22; 1.38]a	0.93 [0.27; 3.25]
Local HT	1.24 [0.54; 2.84]a	0.70 [0.35; 1.39]
Age 81–85, HR (95% CI)
No HT	1 (ref)	1 (ref)
Systemic HT	2.29 [0.41; 12.83]a	1.01 [0.33; 3.11]a
Local HT	2.10 [0.78; 5.66]a	2.15 [0.86; 5.34]a

HR, hazard ratio; CI, confidence interval.

^aUnadjusted risk estimates from Supplementary Table S7, as information on education was missing for > 98% in the oldest birth cohorts.

Note. Due to data being restricted to include those with date of birth before January 1st 1950, there is no data for those aged 51–55 in 2005.